Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist.
作者信息
Shields Ryan K
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
J Infect Dis. 2024 Feb 14;229(2):303-306. doi: 10.1093/infdis/jiad250.
Abstract
摘要
相似文献
1
Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist.应对抗菌药物耐药性威胁的进展与新挑战：传染病药剂师的视角
J Infect Dis. 2024 Feb 14;229(2):303-306. doi: 10.1093/infdis/jiad250.
2
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.抗菌药物敏感性试验：抗菌药物耐药时代临床医生的最新入门指南：来自传染病药师协会的见解
Pharmacotherapy. 2023 Apr;43(4):264-278. doi: 10.1002/phar.2781. Epub 2023 Mar 16.
3
Editorial: Antimicrobial resistance in pediatric infectious diseases: antimicrobial resistance, resistance mechanisms and antimicrobial use.社论：儿童传染病中的抗菌药物耐药性：抗菌药物耐药性、耐药机制及抗菌药物使用
Front Cell Infect Microbiol. 2023 Sep 26;13:1287051. doi: 10.3389/fcimb.2023.1287051. eCollection 2023.
4
[The Role of Pharmacists in AST in Large Hospitals and Their Training].[药师在大型医院抗菌药物管理中的作用及其培训]
Yakugaku Zasshi. 2021;141(11):1257-1260. doi: 10.1248/yakushi.21-00107-3.
5
Role of pharmacists in antimicrobial stewardship programmes.药剂师在抗菌药物管理计划中的作用。
Int J Clin Pharm. 2018 Oct;40(5):948-952. doi: 10.1007/s11096-018-0675-z. Epub 2018 Sep 22.
6
Adding Antimicrobial Stewardship Pharmacists to the Infectious Diseases Compensation Discussion: A More Perfect Union?
Clin Infect Dis. 2024 Jul 19;79(1):271-272. doi: 10.1093/cid/ciad722.
7
Effect of on-call infectious-diseases pharmacists on antibiotic expenditures.随叫随到的传染病药剂师对抗生素支出的影响。
Am J Health Syst Pharm. 2005 Oct 1;62(19):1967-8. doi: 10.2146/ajhp050033.
8
Expanding the scope of the infectious diseases pharmacist in HCT: Beyond antimicrobial stewardship.扩大 HCT 中传染病药剂师的工作范围：超越抗菌药物管理。
Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14094. doi: 10.1111/tid.14094. Epub 2023 Jul 7.
9
Building an Antimicrobial Stewardship Program: Cooperative Roles for Pharmacists, Infectious Diseases Specialists, and Clinical Microbiologists.建立抗菌药物管理计划：药剂师、传染病专家和临床微生物学家的合作角色
Lab Med. 2015 Summer;46(3):e65-71. doi: 10.1309/LMC0SHRJBY0ONHI9.
10
Pharmacist-led antimicrobial stewardship programme in a small hospital without infectious diseases physicians.无传染病专科医师的小型医院中由药剂师主导的抗菌药物管理项目。
Sci Rep. 2022 Jun 9;12(1):9501. doi: 10.1038/s41598-022-13246-6.
引用本文的文献
1
Antibacterial Compounds Isolated from Endophytic Fungi Reported from 2021 to 2024.2021年至2024年报道的从内生真菌中分离出的抗菌化合物
Antibiotics (Basel). 2025 Jun 25;14(7):644. doi: 10.3390/antibiotics14070644.
本文引用的文献
1
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).舒巴坦-他唑巴坦与多黏菌素治疗鲍曼不动杆菌-醋酸钙不动杆菌复合体引起的严重感染患者的疗效和安全性：一项多中心、随机、阳性药物对照、3 期、非劣效性临床研究（ATTACK）。
Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11.
2
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).美国医院耐碳青霉烯类肠杆菌科细菌中碳青霉烯酶的流行病学变化以及氨曲南-阿维巴坦对当代肠杆菌科细菌的活性（2019 - 2021年）
Open Forum Infect Dis. 2023 Jan 31;10(2):ofad046. doi: 10.1093/ofid/ofad046. eCollection 2023 Feb.
3
Within-Host Genotypic and Phenotypic Diversity of Contemporaneous Carbapenem-Resistant Klebsiella pneumoniae from Blood Cultures of Patients with Bacteremia.血培养中同时存在的耐碳青霉烯类肺炎克雷伯菌的宿主内基因和表型多样性。
mBio. 2022 Dec 20;13(6):e0290622. doi: 10.1128/mbio.02906-22. Epub 2022 Nov 29.
4
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.头孢洛扎/他唑巴坦不敏感、碳青霉烯类耐药铜绿假单胞菌的表型和基因型特征。
J Antimicrob Chemother. 2022 Dec 23;78(1):252-256. doi: 10.1093/jac/dkac385.
5
Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside.ESKAPE 病原体的抗生素异质性耐药性：从基础到临床。
Clin Microbiol Infect. 2023 Mar;29(3):320-325. doi: 10.1016/j.cmi.2022.10.018. Epub 2022 Oct 18.
6
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
7
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).欧洲临床微生物学和传染病学会（ESCMID）治疗多重耐药革兰氏阴性杆菌感染的指南（由欧洲重症监护医学学会认可）。
Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.
8
Filling the gaps in the global prevalence map of clinical antimicrobial resistance.填补临床抗菌药物耐药性全球流行情况地图中的空白。
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1). doi: 10.1073/pnas.2013515118.
9
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、耐碳青霉烯肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的治疗指南。
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478.
10
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
Zotero 插件